Background Retinal vein occlusion (RVO) is the second most common retinal vascular
disorder that affected 16.4 million people worldwide in 2008. The last decade has seen new …

Retinal vein occlusion (RVO)-including central RVO, branch RVO, and hemicentral and
hemispheric RVO—is the second most common vascular cause of visual loss, surpassed …

Importance Studies have established the efficacy and safety of aflibercept for the treatment
of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to …

Importance The comparative clinical effectiveness of ranibizumab, aflibercept, and
bevacizumab for the management of macular edema due to central retinal vein occlusion …

Abstract Coronavirus disease 2019 (COVID-19) vaccines are associated with several ocular
manifestations. Emerging evidence has been reported; however, the causality between the …

Retinal vein occlusion (RVO) is the second most prevalent retinal disease. Despite this, the
pathogenic mechanisms and risk factors are not entirely clear. In this article, we review …

Purpose Retinal vascular occlusion is a leading cause of profound irreversible visual loss,
but the understanding of the disease is insufficient. We systematically investigated the age …

Objective: Although several risk factors for retinal vein occlusion (RVO) are known, what
triggers RVO is unclear in many cases. We aimed to evaluate the relevance of multiple risk …

Background While randomized controlled trials (RCTs) are based on strict
inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional …

Purpose To study the prevalence of resolved paracentral acute middle maculopathy (PAMM)
lesions in fellow eyes of patients with unilateral retinal vein occlusion (RVO) and eyes of …